Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of 150 mg Dabigatran Etexilate p.o. in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function in a Monocentric, Open, Parallel-group Design
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Liver disorders
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 26 Jun 2014 New trial record